Our services span the entire lifecycle of product
development and commercialisation, and can be adapted to
suit small local trials or large global programs.
Clinical trials during COVID-19.
Bringing the clinical trial to the patient with innovation and in-home solutions.
ICON provides its full range of clinical, consulting and commercial services across several industry sectors.
A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.
Developing transformative therapies requires a flexible approach.
We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.
ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.
ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
We develop integrated technologies to significantly enhance
the efficiency and productivity of clients’ drug and device
With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
Harmonising data and services for more integrated decentralised clinical trials.
BioPharma companies and Medical Devices manufacturers face
growing operational, regulatory and economic challenges. ICON
provides analysis and key insights on these challenges, with
practical advice and recommendations.
Establishing a platform for improvement
Patient focused research for better outcomes.
ICON regularly contributes thought leadership to industry
media publications and conferences, and has been recognised as
one of the world’s leading Contract Research Organisations
through a number of high-profile industry awards.
7 December, 2022 - Register today.
14 December, 2022 - Register today.
Our mission is to help clients accelerate the development of
drugs and devices that save lives and improve quality of life.
ICON is committed to making a positive impact on our people, environment and our community.
Partners making a difference.
Commentary from EB McLindon on the challenges of patient recruitment and the need for current recruitment methods to evolve, especially for trials involving rare diseases and oncology.